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i g h l i g h t s
AC-263093 previously activated type 2, but not type 1, Neuropeptide FF receptors.
Morphine infusion induced robust tolerance to morphine analgesia (tail ﬂick test).
AC-263093, 10mg/kg i.p., totally reversed this tolerance to 5mg morphine sulfate.
AC-263093 did not induce an analgesic effect in rats never exposed to morphine.
AC-263093 blocked activation of type 1 receptor, further altering balance between types 1 and 2.
r t i c l e i n f o
rticle history:
eceived 29 July 2014
eceived in revised form 8 October 2014
ccepted 9 October 2014
vailable online 20 October 2014
eywords:
orphine tolerance
europeptide FF
europeptide FF receptor
eceptor subtype
a b s t r a c t
Neuropeptide FF (NPFF) modulates opiate actions. It has pro-nociceptive effects, primarily through the
NPFF receptor 1 subtype, and anti-nociceptive effects, primarily through theNPFFR2 subtype. AC-263093
is a small l, organic, systemically active molecule that was previously shown to functionally activate
NPFFR2, but not NPFFR1. It was hypothesized that AC-263093 would attenuate morphine tolerance. Rats
were tested for radiant heat tail-ﬂick latency before and after 5mg/kg morphine sulfate s.c. They were
then rendered morphine-tolerant by continuous subcutaneous infusion of 17.52mg/kg/day morphine
sulfate. On the seventh day of infusion, they were retested for analgesia 10 and 20min after 5mg/kg
morphine sulfate s.c. Tolerance was indicated by reduction of morphine analgesia from the pre-infusion
test. Fifty minutes prior to morphine challenge, rats received either 10mg/kg i.p. AC-263093 or injec-
tion vehicle alone. AC-2623093-treated rats had far smaller tolerance scores than control rats. This drugail ﬂick
piate tolerance
effect was signiﬁcant, p=0.015. The same dose of AC-263093 had almost no analgesic effect in non-
tolerant, saline-infused rats. In vitro experiments revealed that AC-263093 had equal afﬁnity for NPFFR1
and NPFFR2, and functionally inactivated NPFFR1, in addition to its previously shown ability to acti-
vate NPFFR2. Thus, altering the balance between activation of NPFF receptor subtypes may provide one
approach to reversing opiate tolerance.
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY. IntroductionChronic use of opiate narcotic drugs, such as morphine, causes
rug tolerance: a profound loss of potency. These drugs are com-
only used to alleviate chronic pain. Opiate tolerance necessitates
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repeated escalation of narcotic doses, creating major problems in
pain management [1–3].
Chronic morphine administration in the rat results in signiﬁ-
cantly increased levels of NPFF in cerebrospinal ﬂuid [4]. NPFF is
sometimes considered an anti-opiate peptide since it antagonizes
various acute effects of opiate drugs [5–7]. Conversely, antibodies
and antagonists to NPFF administered i.c.v. or s.c. have attenu-
ated morphine tolerance in the rat [8–11]. On the other hand,
spinal administration of NPFF has been shown to potently inten-
sifymorphine analgesia [12].Moreover, spinalNPFF administration
has long-acting, opiate-like analgesic effects [13–15]. These actions
article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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re likely mediated by the release of met-enkephalin [16] and
re naloxone-reversible [17], consistent with pro-opiate actions of
PFF.
Two NPFF receptor subtypes (NPFFR1 and NPFFR2) have been
iscovered [18]. NPFF binds to both, while a series of related
Famide C-terminal peptides, such as NPAF andNPSF, have varying
fﬁnities for these receptor subtypes. Both subtypes are distributed
n the brain, but only NPFFR2 is readily detected in the rat spinal
ord [18–20]. Several reports suggest that the NPFFR2 receptor
s responsible for antinociceptive, or pro-opiate, activity [12–16].
lthough its receptor binding afﬁnities were not measured, Lameh
t al. [21] demonstrated that the compound AC-263093 selectively
timulates functional activation of this receptor subtype. This was
ndicatedby receptormodulationof cAMP levels in cells transfected
ith NPFFR1 or NPFFR2, as well as selection ampliﬁcation tech-
ology (RSAT) which quantiﬁes cellular proliferation dependent
n receptor activation. As would be expected from this receptor
electivity, it also induced antinoceptive effects in multiple in vivo
odels of rodent hyperalgesia. The present study evaluated the
ypothesis that this compound would restore the analgesic effect
f morphine in morphine-tolerant rats. Another experiment deter-
ined whether AC-263093 might have reduced pain sensitivity by
xerting an acute analgesic effect of its own rather than actually
ltering morphine tolerance. The receptor binding afﬁnities of AC-
63093 and related compounds were also measured, as well as
C-263093 functional inhibition of the NPFFR1 receptor, as distin-
uished from binding afﬁnity and lack of functional activation.
. Materials and methods
.1. Approval
These experimental procedures were approved by the UHCL
nimal Care and Use Committee.
.2. Experiment 1: The ability of AC-263093 to reverse morphine
olerance
.2.1. Materials
AC-263093 was synthesized as described previously as
compound 2” [22]. The chemical formula for AC-263093 is 2-(3,4-
ibromobenzylidene) hydrazine carboximidamide hydrochloride.
he structure is shown in Fig. 3.
.2.2. Subjects
Eight male Sprague-Dawley rats (Harlan, Indianapolis, IN)
eighing 405±27g (M± SD)weremaintained on a 12-h light/dark
ycle with food and water ad lib.
.2.3. Apparatus
A radiant heat tail ﬂick apparatus (Stoelting, Wood Dale, IL) was
mployed. The device was calibrated such that a normal, drug-free
at would remove its tail after approximately 3–4 s of heat expo-
ure. The trial was terminated after a maximum of 12 s in order to
revent tissue damage.
.2.4. Inducing morphine tolerance
Under isoﬂurane anesthesia, each ratwas implanted s.c. with an
lzet 2ML1 osmotic pump ﬁlled with morphine sulfate in saline.
ach rat was infused over seven days with 17.52mg/kg/day of
orphine sulfate. This treatment previously resulted in robust
orphine tolerance [11,12]..2.5. Pre-infusion testing (before morphine sulfate infusion)
Rats were injected s.c. with 1.0ml/kg saline as a control for the
ubsequent morphine sulfate injection. The average of three tailetters 584 (2015) 141–145
ﬂick latencies was recorded at 10 and 20min after saline injec-
tion and the average latency was computed for each test. Rats
were then injected i.p. with 1.0ml/kg of 20% dimethyl sulfoxide
(DMSO)/80% saline. (This was a control for the injection vehicle
subsequently used for AC-263093.) Fifty minutes after i.p. injec-
tions, rats received 5mg/kg morphine in saline s.c. This dose was
chosen as the smallest dose that induced near maximal analgesia
(80–90% of the maximum possible effect), thereby providing opti-
mal sensitivity to detecting tolerance. At 10 and 20min after these
injections, the rats were retested for tail ﬂick latencies using the
same protocol. Ten and twenty minutes morphine analgesia scores
were calculated as the increase in average latency from pre- to
post-morphine injection at each post-injection interval expressed
as a percentage of the maximum possible increase, given the
12 s cutoff. Analgesia score as a percentage=100× (post-morphine
latency−pre-morphine latency)/(12 s−pre-morphine latency).
2.2.6. Post-infusion testing (after morphine sulfate infusion)
On the seventh day of infusion, rats were pretested using the
same method as the pre-infusion pretest. AC-263093 was dis-
solved in 0.2ml DMSO and brought up to 1.0ml with saline. An
experimental group of four morphine-tolerant rats were given
i.p. injections of 10mg/kg AC-263093 while a control group
of four morphine-tolerant rats were administered the injection
vehicle (DMSO/saline) alone. This 10mg/kg dose of AC-263093
was previously shown to produce analgesia in hyperalgesic
carrageenan-treated rats and in hyperalgesic rats following spinal
nerve ligation, but not in untreated rats [21]. Fifty minutes after
i.p. injection, rats received morphine injections (5mg/kg s.c.) and
were tested for tail ﬂick latencies 10 and 20min later. The mor-
phine analgesia scores in response to injectionof 5mg/kgmorphine
sulfate were computed as before. Each morphine tolerance score
was calculated as the change in morphine analgesia score from
pre-infusion testing to post-infusion testing. A negative tolerance
score (decrease in morphine analgesia score) indicated morphine
tolerance.
2.3. Experiment 2: Effect of 10mg/kg AC-263093 on tail ﬂick
response in morphine-naïve rats
2.3.1. Subjects
Subjects included eleven male Sprague-Dawley rats with an
averageweight of 293±29g (M± SD),maintained as in Experiment
1.
2.3.2. Procedure
The goal of this procedure was to evaluate any acute analgesic
effect of AC-263093 by itself (without morphine infusion or injec-
tion) in opiate-naïve rats exposed to the same non-drug conditions
as in Experiment 1. Therefore, the same procedures as in Experi-
ment 1 were repeated with the following exceptions: all rats were
infused s.c. for seven days with saline alone, to control for any
effects of osmotic minipump implantation in Experiment 1; only
saline injections were administered before each pre-infusion and
post-infusion set of tail ﬂick tests, so that the subjects were never
exposed to morphine; although each rat experienced pre-infusion
testing as before, the effect of AC-263093 was evaluated only by
post-infusion testing since that compound had been administered
post-infusion in Experiment 1; six rats were assessed for analgesia
before and 60 and 70min after i.p. injection of 10mg/kg AC-263093
in DMSO/saline (10 and 20min after s.c. saline injection); ﬁve con-
trol rats were assessed for analgesia at the same intervals after
injection of DMSO/saline vehicle alone, followed 50min later by
injection by saline s.c.; each rat’s AC-263093 analgesia scores were
the change in tail ﬂick latency from pre- to 60 and 70min post-i.p
injection as a percentage of the maximum possible change, given
ence Letters 584 (2015) 141–145 143
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Fig. 1. Reversal of morphine tolerance by AC-263093. Morphine analgesia scores
are the % of maximum possible increase in latency. Tolerance scores are the change
in these % scores from before to after chronic morphine infusion and injection of
AC263093 (solid line) or vehicle alone (dotted line) 50min. prior to morphine chal-
lenge. Latency is retested 10 and 20min after morphine s.c. *p=0.028 (10min.) and
0.029 (20min.) vs. corresponding pre-infusion morphine analgesia scores.
Fig. 2. AC-263093 (10mg/kg) by itself does not induce analgesia in saline-infused,D.H. Malin et al. / Neurosci
he 12 s cutoff. Note that there were no tolerance scores, since only
he acute effect of AC-263093 was evaluated.
.4. Binding to and inhibition of NPFFR subtypes
.4.1. Materials
The radioligandwas [125I]1DMe-NPFF (D-Tye[125I]-Leu-MePhe-
ln-Pro-Gln-Arg-Phe-NH2) from American Radiolabeled Chemi-
als, Inc (St. Louis, MO; lot#131016, 159Ci/ml, 2200Ci/mmol).
uman NPFFR1 (RBHNF1M, lot 347-677-B) and human NPFFR2
embrane preparations (RBHNF2M, lot 624-755-A) were obtained
rom PerkinElmer (Boston, MA). AC-263093 was synthesized by
cadia Pharmaceuticals.
.4.2. Radioligand binding protocol
Ninety-six well polypropylene plates (U-bottom, Falcon
351190)were preparedwith serial dilutions of test compounds in
inding buffer (50mM Tris–HCL, pH 7.4, 1mM MgCl2, 60mM NaCl,
nd0.5%bovineserumalbumin).Membranes (NPFFR1,0.1g/well;
PFFR2, 1g/well) were thawed rapidly, diluted with binding
uffer and added to the plates. Radioligand (0.016nM 125I-NPFF
or NPFFR1, 0.033nM 125I-NPFF for NPFFR2) was added to make a
nal volume of 200 or 100l/well for NPFFR1 and NPFFR2, respec-
ively. The plates were incubated at room temperature for 2h with
haking. Binding was terminated by ﬁltration through GF/B ﬁlters
presoaked with 0.1% polyethylenimine) with a 96-well harvester
Brandel Inc., Gaithersburg, MD). The ﬁlters were washed with
ce-cold binding buffer (150ml/plate) and allowed to air-dry for
0min. MicroScint-20 cocktail (50l) was added to each dried
ell, and the plates were sealed and counted for 2min/well using
TopCount scintillation counter (PerkinElmer Life and Analytical
ciences, Waltham, MA).
.4.3. Functional inhibition of NPFFR1 receptor
Todetect the ability ofAC-263093 to inhibit functional g-protein
inked receptor activation, RSAT assays of NIH/3T3 cells transfected
ith NPFFR1 were performed as described previously (Lameh et al.
21]) in thepresence or absence of 1MNPAF (a high afﬁnity ligand
or this subtype) and 5M AC-263093.
. Results
.1. Experiment 1: AC-263093 reverses morphine tolerance
Fig. 1 shows the tolerance scores: change from pre- to post-
orphine infusion in analgesia scores (increase in tail ﬂick
atency/maximum possible increase) in response to s.c. morphine
njection. Control rats receiving injection vehicle only prior to
etest responded 10min after morphine injection with analge-
ia scores that were 39.1%±13.1% (M± SEM) lower than their
orresponding pre-infusion scores, a signiﬁcant change, p=0.028
ccording to a one-sample t-test. Their analgesia scores at 20min
ost-morphine were 69.9%±23.1% lower than the corresponding
re-infusion scores, a signiﬁcant difference, p=0.029, according
o one-sample t-test. In contrast, the group pre-treated with AC-
63093 prior to retest decreased their morphine analgesia scores
y only 12.4%±8.89% from their pre-infusion scores 10min after
orphine challenge, a non-signiﬁcant change, p=0.257. They actu-
lly increased their 20min post-morphine scores by 19.6%±12.6%,
hich was also not a signiﬁcant change from pre-infusion scores,
= 0.217. Analysis of variance of these morphine tolerance scores
ith one repeated measures variable (time post-morphine injec-
ion) revealed a signiﬁcant effect of drug (AC-263093 vs. injection
ehicle only), F(1,6) = 11.40, p=0.015 The effect of time post-
orphine injection was not signiﬁcant, F(1,6) = 0.002, p=0.965.opiate-naïve rats. Analgesia scores (% of maximum possible increase in latency from
pretest) 10 and 20min after s.c. saline injection, 60 and 70min after injection with
AC263093 (solid line) or vehicle alone (dotted line).
The interaction effect (drug× time) did not reach signiﬁcance,
F(1,6) = 5.57, p=0.056.
3.2. Experiment 2: 10mg/kg AC-263093 does not induce
analgesia in morphine-naïve rats
Fig. 2 shows theacuteanalgesic effectsofAC-263093or injection
vehicle alone on opiate-naïve rats that were otherwise subjected
to the same procedures as the rats in Experiment 1. As the ﬁgure
shows, there were only analgesia scores observed at 60 and 70min
post-i.p. injections (10 and 20min post-s.c. saline injections). At
60min post-i.p. injection, the vehicle control rats increased their
latencies byonly5.75%±6.45%,while theAC-263093 rats increased
their latencies by only 2.37%±5.05%. At 70min post-i.p. injection,
the control rats had analgesia scores of 3.38%±4.22%, while the
144 D.H. Malin et al. / Neuroscience L
Table 1
Binding afﬁnities of NPFF-related compounds at NPFFR1 and R2 subtypes. pKi is the
negative logarithm of Ki, so that a high value indicates high afﬁnity. N is number of
replicate samples, SD is standard deviation of pKi among those samples.
Ligand hNPFF1 hNPFF2 Fold selectivity
pKi SD N pKi SD N FF1/FF2
AC-263093 7.0 0.1 3 6.9 0.2 3 1
Dansyl-PQR-amide 5.2 0.2 3 4.1 0.3 3 11
Dansyl-PQRF-amide 8.5 0.2 3 8.3 0.3 3 2
Dansyl-RF-amide 8.1 0.1 3 6.0 0.1 3 143
NPFF 9.9 0.3 5 9.6 0.2 4 2
Fig. 3. AC-263093 blocks activation of NPFF1 receptors by neuropeptide AF. RSAT
assays were performed using 1M NPAF or 5M AC-263093 where indicated by
(+) or no drugwhere indicated by (−). Scores are decimal fractions indicating degree
of receptor activation as indicated by levels-galactosidase relative to that induced
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dependence. Further studies are warranted to evaluate the effects
of such compounds on varying degrees of opiate tolerance assessedy NPAF stimulation in the absence of AC-263093. There was virtually zero receptor
timulation under the other conditions.
C-263093 group had scores of 8.33%±6.40%. Two-way ANOVA
ith one repeated measures variable (time) revealed no signiﬁcant
ffects of drug, F(1,9) = 0.170, p=0.900, or of time, F(1,9) = 0.379,
= 0.553, or of interaction (drug× time), F(1,9) = 2.036, p=0.187.
.3. Receptor binding
Table 1 presents the binding afﬁnities of various NPFF-related
ompounds toNPFFR1andNPFFR2. Surprisingly, AC-263093bound
ith approximately equal afﬁnity to both receptor subtypes.
ansyl-PQRamide, andDansyl-RFamideshowedhighselectivity for
PFFR1, while the natural peptide NPFF and Dansyl-PQRFamide
ad lower selectivity for NPFFR1.
.4. Functional inhibition of NPFFR1
Fig. 3 illustrates the ability of 1MNPAF to functionally activate
-protein-linked NPFFR1 activity as indicated by increased levels
f -galactosidase [21]. It also shows the complete abolition of this
ffect by 5M AC-263093.etters 584 (2015) 141–145
4. Discussion
Systemic administration of AC-263093 totally reversed robust
morphine tolerance to 5mg/kg morphine sulfate induced by seven
days of continuous morphine sulfate infusion. This cannot be
explained by an analgesic effect of AC-263093 in itself, since the
same dose had no signiﬁcant effect on tail ﬂick latencies in saline-
infused, opiate-naïve rats, consistent with its previously reported
lack of analgesia in untreated rats [21]. This same dose previously
produced analgesia in hyperalgesic carrageenan-treated rats and in
ratswith spinal nerve ligation [21]. Sinceonly type2NPFF receptors
are readily detected in the spinal cord, this suggests that AC-
263093 likely activates NPFFR2 function in vivo. Thus, the present
results raise thepossibility that stimulation ofNPFFR2provides one
approach for reversing opiate narcotic tolerance.
However, binding data in the current study indicates that AC-
263093 binds with approximately equal afﬁnity to NPFFR1 and
NPFFR2. Despite this, AC-263093 previously failed entirely to func-
tionally stimulate NPFFR1-mediated actions in vitro. At the same
dose employed in the present study, it also failed to exert any pro-
nociceptive actions that might be expected with NPFFR1 activation
[21]. Compounds that bind receptors but do not produce agonist
responses generally act as antagonists. Lameh et al. [21] did not test
for AC-263093 functional antagonist activity at the NPFF1 receptor,
but we now report that AC-263093 does have this effect. This sug-
gests that AC263093 inhibits the pro-nociceptive NPFFR1 subtype,
in addition to stimulating the anti-nociceptive NPFFR2. While AC-
263093 has only moderate afﬁnity for NPFF receptors, its afﬁnity
is far higher than the NPFF receptor afﬁnities of dansyl-PQRamide,
which exerted powerful actions against morphine tolerance [10].
The binding data presented in Table 1, in combination with
results of earlier behavioral experiments, sheds light on the
function of NPFFR1. The NPFFR1-selective systemically active
agonists RFamide and dansyl-PQRFamide precipitated morphine
abstinence syndrome [23,24], while the NPFFR1-selective syste-
mically active antagonist dansyl-PQRamide attenuated morphine
tolerance, restoring the analgesic effect of morphine [10]. Thus AC-
263093 reversal of morphine tolerance coupled with its functional
inhibition of NPFFR1 is consistent with the hypothesis that the
NPFFR1 stimulation has anti-opiate effects in subjects that have
been exposed to chronic opiate administration, while NPFFR1 inhi-
bition may alleviate some effects of such opiate exposure. Whether
through stimulation of NPFFR2 or antagonism of NPFFR1, altering
the balance in favor of NPFFR2 over NPFFR1 stimulation appears to
markedly attenuate morphine tolerance. The relative contribution
of these two actions to tolerance reversal by AC-263093 could be
clariﬁed by adding a selective NPFFR2 antagonist. Unfortunately, to
our knowledge, no such compound is currently available.
Opiate-like analgesic NPFF effects have been clearly demon-
strated, especially with spinal administration [8,12]. This might
appear inconsistent with reports that NPFF can inhibit morphine
analgesia [7,25] and precipitate morphine withdrawal syndrome
[26], or that antibodies [9] and antagonists against NPFF [10,11]
restore sensitivity to morphine in opiate-tolerant rats. Research
such as thepresent study, utilizingNPFF receptor subtype-selective
compounds, may help resolve this seeming paradox. The failure of
AC-263093 to produce an analgesic effect in non-tolerant rats also
suggests that such receptor subtype-selective compounds might
attenuate opiate tolerance without substituting opiate-like actions
conducive to addiction liability. Thus, development of drugs with
differential actions on NPFFR1 and NPFFR2 might provide one pos-
sible approach to the treatment of opiate narcotic tolerance andby differing brain-mediated and spinally mediated measures of
analgesia.
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